Flagg Flanagan, Chairman and CEO 

Oct. 10 | 9:45am | Ecolab Life Sciences Ballroom 

Salt Lake City, UT 


DiscGenics is a privately held, clinical-stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’s first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy in development for symptomatic, mild to moderate lumbar disc degeneration. In a recent FDA-allowed prospective, randomized, double-blind, vehicle- and placebo-controlled, multicenter Phase I/II clinical study, IDCT safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of life, and pain medication usage out to two years post-injection in patients with lumbar DDD, suggesting a regenerative effect. IDCT has Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations granted by the U.S. FDA.


By using this website you agree to accept our Privacy Policy and Terms & Conditions